Replay available

Viking Therapeutics, Inc. (0VQA) Q1 2026 Earnings Call

Viking Therapeutics, Inc. (LSE: 0VQA) Q1 2026 earnings conference call, held 2026-04-29. Replay captured from the company's public earnings webcast.

Wed, April 29, 2026 at 4:30 PMendedReplay
Viking Therapeutics, Inc. (0VQA) Q1 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

William Wood

Analyst, B. Riley Securities

Brian Land

President and Chief Executive Officer

Steve Seedhouse

Analyst, Cantor Fitzgerald

Ryan Desner

Analyst, Raymond James

Thomas Smith

Analyst, Learing Partners

Yale Jen

Analyst, Laidlaw & Company

Andy Shea

Analyst, William Blair

Hardik Parikh

Analyst, JPMorgan

Roger Song

Analyst, Jefferies

Neil Abishan

Chief Commercial Officer

Stephanie Dyes

Manager, Investor Relations

Jay Olson

Analyst, Oppenheimer

Brian Amin

Analyst, Piper Sandler

Greg Zanti

Chief Financial Officer

Replay transcript excerpt

Welcome to the Viking Therapeutics First Quarter twenty twenty six Financial Results Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a reminder, this conference call is being recorded today, 04/29/2026. I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Dias. Thank you, and over to you. Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO and Greg Zanti, Viking's CFO. Before we begin, I'd like to caution that comments made during this conference call today, 04/29/2026, will contain forward looking statements under the Safe Harbor provisions of The U. S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones. Forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lian for his initial comments. Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the first quarter ended 03/31/2026, and review recent progress with our pipeline programs and operations. During the first quarter, we made signifi...

More from Viking Therapeutics, Inc.